IFS Securities analyst David Bouchey upgraded Loxo Oncology (NASDAQ: LOXO) from Market Perform to Outperform with a price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE